Novavax Inc. ($NVAX) Stock Forecast: Up 5.3% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company recognized for its protein-based vaccines. The stock experienced a significant increase in value today amidst a day of mixed trading activity in the market.

Why is Novavax Inc. going up?

NVAX stock is up 5.3% on May 20, 2026 15:56

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Inc. stock underperforms Monday when compared to competitors

Novavax Inc. (NVAX) shares experienced a 1.43% decline on Monday, closing at $8.93. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the NASDAQ Composite Index falling. This marks the second consecutive day of losses for Novavax stock.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-monday-when-compared-to-competitors-00c5452c-69592a4be554

Why (NVAX) Price Action Is Critical for Tactical Trading

This article analyzes Novavax Inc. (NVAX) using AI models, highlighting a weak near-term sentiment but strong mid and long-term outlooks. It presents three institutional trading strategies, including position trading, momentum breakout, and risk hedging, to capitalize on NVAX's potential movements. The analysis emphasizes risk-reward setups and multi-timeframe signal analysis for tactical trading decisions.

https://news.stocktradersdaily.com/news_release/149/Why_NVAX_Price_Action_Is_Critical_for_Tactical_Trading_051826020402_1779127442.html

Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus

Novavax Inc's stock is experiencing volatility following its latest quarterly figures and updated Covid-19 vaccine strategy. The company, known for its protein-based vaccines, is navigating a shift from mass vaccination campaigns to seasonal booster markets, requiring a focus on cost reduction and diversification into broader respiratory and combination vaccines. Investors are keenly watching its ability to compete in the US seasonal respiratory vaccine market and secure future partnerships.

https://www.ad-hoc-news.de/boerse/news/ueberblick/novavax-inc-stock-us66987v1098-earnings-volatility-and-covid-vaccine/69360054

Novavax, Inc. Trade Ideas — BOATS:NVAX

This article compiles various trade ideas and analyses for Novavax (NVAX) from different traders on TradingView. The commentary covers both technical and fundamental aspects, discussing the company's cyclical nature, strategic efforts to improve commercial performance, resolution of the Gavi dispute, and long-term prospects including new vaccine developments. While some analysts are bullish on NVAX's potential for significant gains, others highlight risks associated with its price volatility and upcoming earnings reports.

https://www.tradingview.com/symbols/BOATS-NVAX/ideas/page-3/

Novavax Inc stock (US6707721049): vaccine specialist in focus after latest COVID shot update

Novavax Inc. remains a key focus for investors as it updates on its latest protein-based COVID-19 vaccine and funding. The company aims to stabilize its business after the pandemic and shift towards a sustainable seasonal model, emphasizing updated vaccine formulations and combination shots for COVID-19 and influenza. Its future success hinges on regulatory decisions, seasonal demand, and diversification beyond its primary COVID vaccine product.

https://www.ad-hoc-news.de/boerse/news/ueberblick/novavax-inc-stock-us6707721049-vaccine-specialist-in-focus-after-latest/69358346

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

D.R. Horton Inc. ($DHI) Stock Forecast: Up 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.9% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 7.5% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 5.0% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 5.9% Today

Novavax Inc. Price History

07.04.2026 - NVAX Stock was down 7.6%

• Despite a decline in revenue and a shift to a net loss in Q1 2026, Novavax's stock surged by 17.4%. Investors seemed to focus on the company's new partnership approach and future potential earnings rather than its financial results.
• Novavax initially saw its stock rise due to strong first-quarter financial results, which surpassed sales expectations and emphasized strategic collaborations. Nevertheless, the market sentiment shifted, resulting in the recent bearish trend.
• Novavax's stock had been performing well in recent trading sessions, outpacing competitors and benefiting from a favorable market environment. Profit-taking activities today likely triggered the observed bearish movement.

07.04.2026 - NVAX Stock was up 4.1%

• Despite facing a significant revenue drop and transitioning to a net loss in Q1 2026, Novavax saw a 17.4% increase in its stock value, indicating investor confidence in its shift to an asset-light, partnership-focused business strategy.
• The company's Q1 financial performance surpassed expectations, surpassing sales forecasts and demonstrating a strengthened financial position through new credit facilities and key partnerships, driving the positive movement in Novavax's stock.
• Novavax reiteration of its 2026 sales outlook, combined with optimistic technical analysis signaling a decrease in downward pressure, further bolstered investor confidence, contributing to the stock's robust performance.
• Novavax's strong stock performance was also evidenced by its outperformance relative to competitors on a flourishing trading day, during which both the NASDAQ Composite and Dow Jones Industrial Average experienced significant gains.

13.04.2026 - NVAX Stock was down 5.2%

• Following positive updates like collaborations with Pfizer and Sanofi, Novavax (NVAX) saw a rise in stock value but observed a downward trend in the current trading session.
• The company's weaker market performance compared to its competitors hints at a potential shift in investor sentiment, leading to profit-taking activities or concerns about its future growth.
• Mixed signals from technical indicators signaling a strong buy stance while options data suggests a preference for downside protection, indicating uncertainty surrounding NVAX's future direction.
• Despite recent positive developments propelling Novavax forward as a growth-oriented player in the vaccine industry, persistent challenges related to profitability and debt likely contributed to today's negative market movement.

30.03.2026 - NVAX Stock was up 6.1%

• The upcoming release of Novavax's first-quarter 2026 financial results created excitement among investors.
• A director of the company showed confidence in Novavax's future by exercising Restricted Stock Units (RSUs), which positively influenced investor sentiment.
• Despite recent underperformance, Novavax's stock experienced a notable upturn today, potentially linked to growing optimism about the company's financial prospects and operational achievements.
• The stock's bullish movement may have been influenced by broader market dynamics or sector-specific developments benefitting biotech firms like Novavax.

06.04.2026 - NVAX Stock was up 14.4%

• Novavax (NVAX) stock exhibited robust bullish growth, surpassing industry peers and the general market.
• Despite predictions of a notable decline in year-on-year revenue, Novavax's stock price surged, potentially influenced by positive outlook or expectations regarding the upcoming earnings.
• The investment stake by Vanguard Capital Management, a significant yet passive investor, could have also played a role in the favorable market dynamics.
• Observers are eagerly anticipating Novavax's financial results for the first quarter of 2026, with the impending disclosure likely fueling the current positive momentum in the stock price.

06.04.2026 - NVAX Stock was up 19.1%

• Novavax reported first-quarter revenue of $139.5 million, surpassing estimates by a significant margin, showcasing strong financial performance.
• The company's revenue was driven by milestone payments from vaccine supply and licensing deals, offsetting declining demand for its COVID-19 vaccine.
• Novavax's strategy of licensing its vaccine technology to other pharmaceutical companies has helped insulate it from uncertainties and cut costs, contributing to its positive earnings report.
• Despite facing pressure from activist investors and missing revenue forecasts in the past, Novavax's stock outperformed competitors on the back of its strong financial results, indicating investor confidence in the company's future prospects.

20.04.2026 - NVAX Stock was up 5.3%

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

08.04.2026 - NVAX Stock was up 8.8%

• NVAX's stock exhibited strong bullish movement recently.
• The filing of a Form 144 Notice of Proposed Sale of Securities introduced some initial uncertainty but was later overshadowed by positive developments.
• NVAX's participation in the BofA Securities 2026 Health Care Conference was met with investor interest and confidence in the company's future.
• A surprising Q1 revenue beat was attributed to a significant deal with Pfizer and a shift towards a licensing model, illustrating NVAX's agility and innovation in a competitive market, leading to the positive movement in its stock price.

11.04.2026 - NVAX Stock was down 8.4%

• Novavax has shown positive developments lately, including strong Q1 earnings and partnerships with Pfizer and Sanofi; however, the stock trended bearishly today.
• Investor concerns may have arisen due to the filing of a Form 144 Notice of Proposed Sale of Securities, potentially leading to selling pressure on the stock.
• Participation in the upcoming BofA Securities 2026 Health Care Conference could offer Novavax a platform to address investor uncertainties and restore market confidence.
• Differing opinions from technical indicators signaling a strong buy and options data pointing to downside protection by the "smart money" likely contributed to the bearish sentiment surrounding the stock.

11.04.2026 - NVAX Stock was down 5.6%

• Today, NVAX stock experienced marked bearish activity attributed to profit-taking by investors following a recent strong rally.
• Positive developments, such as a robust Q1 earnings performance, a significant deal with Pfizer, and an expanded partnership with Sanofi, were overshadowed by concerns regarding negative equity and cash depletion, impacting investor confidence.
• The disclosed insider plan to sell securities, according to an SEC filing, likely contributed to the stock's decline.
• NVAX's comparative underperformance against industry peers amid a broader market downturn indicates the potential impact of general market conditions on today's bearish trend.

08.04.2026 - NVAX Stock was up 13.4%

• Novavax's stock experienced a strong bullish movement of 13.98% following a robust Q1 earnings report and positive developments in its COVID-19 vaccine technology, driven by the following factors:
• The announcement of a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi boosted investor confidence in the company's future growth potential.
• The unexpected revenue beat in Q1, amounting to $139.5 million, surpassed analysts' expectations and showcased Novavax's ability to pivot towards a licensing model, reducing its reliance on direct vaccine sales.
• Participation in the BofA Securities 2026 Health Care Conference further highlighted Novavax's strategic positioning and potential for future collaborations and advancements in the healthcare industry.
• Despite a slight underperformance compared to competitors on a previous trading day, the overall positive sentiment surrounding Novavax's recent developments and financial outlook contributed to the bullish market movement.

14.04.2026 - NVAX Stock was down 5.0%

• NVAX stock closed at $9.23, showing a bearish movement of 4.05% today.
• Despite recent positive news related to partnerships and earnings, NVAX underperformed its competitors and the broader market.
• The mixed trading session and market sentiment likely played a role in the bearish movement of NVAX stock.
• Investors, especially the "smart money," exhibit caution towards the stock's long-term prospects. Technical indicators lean towards a strong buy, while options data signal a preference for downside protection.